NBW Capital LLC Has $1.76 Million Stake in Blueprint Medicines Corporation (NASDAQ:BPMC)

NBW Capital LLC reduced its stake in Blueprint Medicines Corporation (NASDAQ:BPMC) by 41.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,648 shares of the biotechnology company’s stock after selling 24,708 shares during the period. NBW Capital LLC owned approximately 0.09% of Blueprint Medicines Corporation worth $1,756,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. SG Americas Securities LLC increased its stake in Blueprint Medicines Corporation by 23.3% during the second quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 778 shares during the period. Prudential Financial Inc. increased its stake in Blueprint Medicines Corporation by 6.0% during the first quarter. Prudential Financial Inc. now owns 17,304 shares of the biotechnology company’s stock worth $692,000 after purchasing an additional 984 shares during the period. Legal & General Group Plc increased its stake in Blueprint Medicines Corporation by 31.8% during the first quarter. Legal & General Group Plc now owns 5,884 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,419 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Blueprint Medicines Corporation by 10.2% during the first quarter. Metropolitan Life Insurance Co. NY now owns 17,155 shares of the biotechnology company’s stock worth $686,000 after purchasing an additional 1,589 shares during the period. Finally, Fiduciary Trust Co. increased its stake in Blueprint Medicines Corporation by 21.5% during the second quarter. Fiduciary Trust Co. now owns 12,468 shares of the biotechnology company’s stock worth $632,000 after purchasing an additional 2,203 shares during the period. Hedge funds and other institutional investors own 90.71% of the company’s stock.

A number of equities analysts have recently commented on BPMC shares. Jefferies Group LLC reissued a “buy” rating and set a $56.00 price objective on shares of Blueprint Medicines Corporation in a research report on Tuesday, September 5th. Canaccord Genuity reissued a “buy” rating and set a $56.00 price objective on shares of Blueprint Medicines Corporation in a research report on Monday, September 11th. BidaskClub raised Blueprint Medicines Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research raised Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $79.00 price objective (up from $64.00) on shares of Blueprint Medicines Corporation in a research report on Wednesday, September 20th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $63.47.

In other Blueprint Medicines Corporation news, Director Daniel Lynch sold 2,500 shares of Blueprint Medicines Corporation stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $60.00, for a total value of $150,000.00. Following the sale, the director now owns 209,342 shares of the company’s stock, valued at approximately $12,560,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony L. Boral sold 5,000 shares of Blueprint Medicines Corporation stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $48.60, for a total value of $243,000.00. Following the completion of the sale, the insider now directly owns 5,000 shares in the company, valued at approximately $243,000. The disclosure for this sale can be found here. Insiders have sold a total of 69,305 shares of company stock worth $3,606,782 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This news story was first reported by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://baseballnewssource.com/markets/blueprint-medicines-corporation-bpmc-shares-sold-by-nbw-capital-llc/1699264.html.

Shares of Blueprint Medicines Corporation (NASDAQ BPMC) traded up 1.707% during trading on Tuesday, reaching $65.255. The company had a trading volume of 30,356 shares. The firm has a 50-day moving average price of $60.49 and a 200-day moving average price of $49.20. The company’s market capitalization is $2.55 billion. Blueprint Medicines Corporation has a 52-week low of $25.08 and a 52-week high of $71.67.

Blueprint Medicines Corporation (NASDAQ:BPMC) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.11). The company had revenue of $5.89 million during the quarter, compared to analyst estimates of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The business’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same period last year, the company earned ($0.70) EPS. On average, analysts predict that Blueprint Medicines Corporation will post ($3.66) EPS for the current fiscal year.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cora Becomes New Manager for Boston Red Sox
Alex Cora Becomes New Manager for Boston Red Sox
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends


Leave a Reply

 
© 2006-2017 BBNS.